Evofem Biosciences, Inc.
Evofem Biosciences, Inc. (EVFM): 3 pipeline candidates · ~4 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
4.4 months
D/E -1.03 · 1% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for Evofem Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.0M
Cash
$2.4M
Quarterly Burn
$2.4M
Runway
4.4 mo
Revenue
$899K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Sep 2023Institutional holders
1
Total value held
$0
| Holder | Shares | Value |
|---|---|---|
| bessemer group inc | 1 | $0 |
Frequently asked questions
How many drug candidates are in Evofem Biosciences, Inc.'s pipeline?
Evofem Biosciences, Inc. (EVFM) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Evofem Biosciences, Inc.'s lead drug candidate?
Evofem Biosciences, Inc.'s most advanced tracked candidate is phexx (Approved) for prevention of pregnancy.
What is Evofem Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Evofem Biosciences, Inc. has approximately 4.4 months of cash runway.
What is Evofem Biosciences, Inc.'s market capitalization?
Evofem Biosciences, Inc.'s market capitalization is approximately $1.0M.
Who is the CEO of Evofem Biosciences, Inc.?
Ms. Saundra Pelletier is the chief executive officer of Evofem Biosciences, Inc. (EVFM).
Get the full picture on Evofem Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.